An 80-year-old man with chronic renal failure (CRF) had pure red cell aplasia (PRCA) 9 months after starting the subcutaneous administration of recombinant human erythropoietin alfa (rHuEPO-α). Owing to the advanced renal failure, conventional immunosuppressive therapies were not practicable. It was decided to administer rituximab (4 cycles of 375 mg/m 2/wk). PRCA was treated successfully with rituximab. The administration of rHuEPO-α then was resumed via the intravenous route with a satisfactory correction of anemia (12 months after the EPO-α rechallenge the patient is still transfusion independent). To the authors' knowledge, this is the first report of (1) a successful treatment with rituximab with CD20 depletion in a CRF patient with PRCA and (2) a successful intravenous resumption of the same rHuEPO-α.

Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia

ASCANI, Stefano;
2004

Abstract

An 80-year-old man with chronic renal failure (CRF) had pure red cell aplasia (PRCA) 9 months after starting the subcutaneous administration of recombinant human erythropoietin alfa (rHuEPO-α). Owing to the advanced renal failure, conventional immunosuppressive therapies were not practicable. It was decided to administer rituximab (4 cycles of 375 mg/m 2/wk). PRCA was treated successfully with rituximab. The administration of rHuEPO-α then was resumed via the intravenous route with a satisfactory correction of anemia (12 months after the EPO-α rechallenge the patient is still transfusion independent). To the authors' knowledge, this is the first report of (1) a successful treatment with rituximab with CD20 depletion in a CRF patient with PRCA and (2) a successful intravenous resumption of the same rHuEPO-α.
2004
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/160306
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 18
social impact